Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Vaccine and Antibiotics Stabilized so Refrigeration is not Needed

Published: Monday, August 06, 2012
Last Updated: Monday, August 06, 2012
Bookmark and Share
NIH study could pave way for development of enhanced delivery and storage in third world, save billions in cost.

Researchers funded by the National Institutes of Health have developed a new silk-based stabilizer that, in the laboratory, kept some vaccines and antibiotics stable up to temperatures of 140 degrees Fahrenheit.

This provides a new avenue toward eliminating the need to keep some vaccines and antibiotics refrigerated, which could save billions of dollars every year and increase accessibility to third world populations.

Vaccines and antibiotics often need to be refrigerated to prevent alteration of their chemical structures; such alteration can result in less potent or ineffective medications.

By immobilizing their bioactive molecules using silk protein matrices, researchers were able to protect and stabilize both live vaccines and antibiotics when stored at higher than recommended temperatures for periods far longer than recommended.

The research was led by grantees of NIH's National Institute of Biomedical Imaging and Bioengineering (NIBIB), David Kaplan, Ph.D., and Jeney Zhang, Ph.D. candidate, at Tufts University School of Engineering in Medford, Mass.

The National Eye Institute and the National Institute of Dental and Craniofacial Research at NIH also contributed to this research. The researchers reported on their findings in the online issue of Proceedings of the National Academy of Sciences on July 9, 2012.

"This truly exciting development is the culmination of years of creative exploration and research focused on a major problem in the delivery of health care. Dr. Kaplan and his team have done a masterful job at both understanding the key properties of silk, and applying these insights to a global medical challenge," said NIBIB Director Roderic I. Pettigrew, Ph.D., M.D.

Pettigrew continued, "This is also a wonderful validation of the type of team science we see in our Biotechnology Resource and Development Centers and their ability to combine cutting edge science in a number of fields to a variety of health needs."

Pettigrew also points out that the next step is to test it in the field.

Keeping medications cold from production until they are used in treatment is a costly process, accounting for as much as 80 percent of the price of vaccinations.

The need for a cold chain has been a difficulty for health care providers, aid organizations, scientists and pharmaceutical companies for decades, especially in settings where electricity is limited.

Failures in the chain result in the loss of nearly half of all global vaccines, according to researchers.

In an attempt to solve this problem, Kaplan and his lab have been working extensively with silk films that essentially wrap up the live bioactive molecules present in antibiotics and vaccines.

This protects these essential bioactive elements, and so can greatly extend the shelf-life of the medication. Silk is used because it is a protein polymer with a chemistry, structure, and assembly that can generate a unique environment, making it an attractive candidate for the stabilization of bioactive molecules over extended periods of time.

To test their new silk stabilizers, Kaplan's team stored the measles, mumps, and rubella (MMR) vaccines for six months at the recommended 39.2 degrees Fahrenheit, as well as at 77, 98.6 , and 113 degrees Fahrenheit.

The results show that encapsulation in the new silk films maintained the potency with minimal loss over time and enhanced stability, even at very high storage temperatures.

Similarly, antibiotics entrapped in silk films maintained near optimal activity even at temperatures as high as 140 degrees. In addition, Kaplan's group found that these silk films had the added benefit of protecting one antibiotic against the detrimental effects of light exposure.

The silk stabilizers are likely to combine well with Kaplan's previously developed silk microneedle system. These tiny needles can deliver medication directly to skin cells that contain a specified antigen.

This targeted approach permits administration of lower doses of medication or vaccine and generates longer-lasting immune responses. The combination could prove to be a simple way to stabilize, distribute, and deliver the medication in one system.

Thus, for vaccines and antibiotics, the use of a silk carrier reduces the detrimental effects of heat and humidity.

"New studies are already under way," says Dr. Kaplan. "We have already begun trying to broaden the impact of what we're doing to apply to all vaccines. Based on what we've seen with other proteins, peptides, and enzymes, there's no reason to believe that this wouldn't be universal. This could potentially eliminate the need for a cold-chain system, greatly decreasing costs and enabling more widespread availability of these life-saving drugs."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.
Tuesday, November 10, 2015
NIH Announces High-Risk, High-Reward Research Awardees
NIH to fund 78 awards to support highly innovative biomedical research.
Wednesday, October 07, 2015
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Thursday, August 27, 2015
Large Percentage of Youth with HIV May Lack Immunity to Measles, Mumps, Rubella
NIH study finds those vaccinated before starting modern HIV therapy may be at risk.
Tuesday, August 18, 2015
NIH-funded Vaccine for West Nile Virus Enters Human Clinical Trials
Enrollment is expected to be completed by December 2015.
Tuesday, July 07, 2015
Douglas Lowy Named Acting Director of the National Cancer Institute
Lowy’s research includes the biology of papillomaviruses and the regulation of normal and neoplastic growth.
Tuesday, April 07, 2015
Experimental Ebola Vaccine Safe, Prompts Immune Response
Results from US government-sponsored phase 1 trial of VSV vaccine reported.
Thursday, April 02, 2015
Ebola Test Vaccines Appear Safe in Phase 2 Liberian Clinical Trial
Liberia-U.S. partnership planning Phase 3 trial and study of Ebola survivors.
Friday, March 27, 2015
Strengthening the Immune System’s Fight Against Brain Cancer
NIH-funded research suggests novel way to improve vaccine efficacy in brain tumors.
Friday, March 20, 2015
NIH-Sponsored HIV Vaccine Trial Launches In South Africa
Early-stage trial aims to build on RV144 results.
Thursday, February 19, 2015
Ebola Vaccine Trial Opens in Liberia
Study led by Liberia-NIH partnership will test two experimental vaccines.
Tuesday, February 03, 2015
NIAID/GSK Experimental Ebola Vaccine Appears Safe, Prompts Immune Response
Results from NIH Phase 1 clinical trial support accelerated development of candidate vaccine.
Friday, November 28, 2014
NIH Begins Early Human Clinical Trial of VSV Ebola Vaccine
Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health’s Clinical Center in Bethesda, Maryland.
Thursday, October 23, 2014
Candidate H7N9 Avian Flu Vaccine Works Better With Adjuvant
Results of large NIH-sponsored trial demonstrate improved vaccine response when an adjuvant was used.
Wednesday, October 08, 2014
NIH Awards Seven New Vaccine Adjuvant Discovery Contracts
Total funding for these contracts reach approximately $70 million over five years.
Tuesday, October 07, 2014
Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos